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a  b  s  t  r  a  c  t
Since  the  ﬁrst article  about  bisphosphonate-related  osteonecrosis  of  the jaw (BRONJ)  was  published  in
2003,  clinical  and  basic  research  for BRONJ  has continued  worldwide  to understand  this  novel  disease.
Several  organizations  have  proposed  the  deﬁnition,  diagnostic  criteria,  risk  factors,  and  treatment  strat-eywords:
steonecrosis
isphosphonate
steoclast
egy  for  BRONJ.  Recently,  some  new  drugs  used  for cancer  patients  such  as  bevacizumab  and  sunitinib
have  also  been  reported  to  be  involved  in  osteonecrosis  of  the  jaw  (ONJ).  Because  ONJ  appears  to be ini-
tially  derived  from  osteoclast  inhibition,  a  new  category  of diseases  named  as “drug-related  osteoclastic
disease  of  the  jaw”  may  be  assumed.  Considering  the  accumulated  knowledge  related  to  BRONJ,  including
osteoclast  biology,  bisphosphonate  pharmacology,  animal  experiments,  and  clinicopathological  ﬁndings,evalonate a  perspective  of BRONJ  from  the  pathophysiological  viewpoint  is  proposed  in  this review.
© 2012 Japanese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
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. Introduction
The number of the patients with bisphosphonate-related
steonecrosis of the jaw (BRONJ) has increased year by year since
arx ﬁrst reported cases of osteonecrosis of the jaw (ONJ) occur-
ing in patients with multiple myeloma treated with intravenously
dministered bisphosphonate in 2003 [1]. The disease concept of
RONJ seems to be established now since many articles and reviews
bout BRONJ have been published.
Bisphosphonate (BP) was originally developed as a drug to treat
one resorbing diseases such as multiple myeloma and bone metas-
asis, whose typical origins are breast cancer and prostate cancer, as
ell as tumor-related hypercalcemia, and then used for the patients
ith osteoporosis to prevent their pathological fracture. In Japan,
pproximately 3 million patients have received BP therapy. A spe-
iﬁc target cell of BP is osteoclast which plays a central role in
hysiological and pathological bone resorption.
Since BP possesses a pyrophosphate-like structure, whose
ydroxyl group confers a strong afﬁnity to the hydroxyapatite, 80%
f BP administered intravenously or orally deposits to the bones.
he half life of BP in humans, which is poorly metabolized by bio-
ogical enzymes, is thought to be about 10 years, and thus BP may
e enriched in the bones, to where osteoclasts, which differentiate
rom bone marrow stem cells, migrate and adhere to function. That
s why BP was expected to work selectively on osteoclasts with-
ut adverse effects. Nitrogen-containing BP (nBP) has more potent
bility to inhibit mineral dissolution and higher potency to induce
RONJ than early BP without nitrogen-containing side-chain [2]. In
his review, “BP” occasionally indicates both nBP and early BP.
Like  BP, denosumab, which is anti-human RANK ligand (RANKL)
onoclonal antibody and developed to inhibit osteoclasts for the
reatment of bone-resorbing diseases, is also suspected to be
nvolved in the occurrence of ONJ that is similar to BRONJ [3,4]. The
ymptoms seen in chronic osteomyelitis of the jaw occurring in the
atients with osteopetrosis, in which osteoclast functions are inhib-
ted by a genetic mutation, also seem to be similar to those of BRONJ.
ince these lesions appear to be derived from osteoclast inhibition,
e could classify them into a new category of diseases presumably
amed as “drug-related osteoclastic disease of the jaw”. This idea is
ased on the concept that the “osteoclast is a self-defense regulator
f the jaw.” The defense mechanism of the jaw should be impaired
n the lack of osteoclasts, which is liken to that we become sus-
eptible to infection when our immune cells are inhibited. In this
eview, hence, the clinical as well as pathophysiological aspects of
RONJ will be discussed according to this concept.
. Incidence of and risk factors for BRONJ
.1. Incidence
The incidence of BRONJ in the early USA report was 0.8–12%
ith intravenous BP and 0.7/100,000 (0.0007%) person-years of
xposure with oral BP [5]. In Europe, the incidence was 95/100,000
0.095%) person-years of exposure with intravenous administra-
ion and 1/100,000 (0.001%) person-years of exposure with oral
dministration [6]. BRONJ occurred in 1.15% of intravenously
dministered patients and in 0.04% of the orally administered
atients in Australia [7]. Another report from the USA indicated that
he incidence of BRONJ was 0.1% with oral BP administration [8].
aken together, these reports suggest that the incidence of BRONJ
ith oral BP is 0.01–0.1%.
Most  of the patients taking oral BP have osteoporosis. Approx-
mately 20% of the 10 million osteoporosis patients in Japan are
hought to be treated with medication including BPs. As the elderly
opulation increases, the number of osteoporosis patients takingtional 10 (2013) 1– 8
oral  BP will increase and the period for BP administration will pro-
long, which will result in an increased incidence of BRONJ. Actually,
a nationwide retrospective cohort study with a questionnaire on
BRONJ in Japan, which was undertaken by the Japanese Society of
Oral and Maxillofacial Surgeons, demonstrated that 263 cases of
BRONJ occurred in the entry hospitals from 2006 to 2008, and 39.5%
of them were patients taking oral BPs [9].
2.2. Tooth extraction
Among  various risk factors, including glucocorticoids (GCs),
anti-cancer drugs, alcohol, smoking, and malnutrition, to make
patients susceptible to BRONJ, tooth extraction and other surgi-
cal procedures to the jaws are most problematic to dentists and
oral and maxillofacial surgeons. Tooth extraction raised the inci-
dence of BRONJ about 8-fold, from 0.04% to 0.34% in the oral
BP-administered patients and from 1.15% to 9.1% in the intravenous
BP-administered patients in Australia [7]. BRONJ occurred in 6%
in 66 patients orally taking aledronate after tooth extraction [10].
Tooth extraction was  related to 77% of BRONJ cases occurring in the
patients into whom BP were administered intravenously [11]. Sur-
gical damage to the jaw, especially alveolar bone, is likely to be the
most potent trigger to BRONJ while the immunosuppressive agents
such as GCs and anti-cancer drugs, could lower the threshold for its
occurrence.
Without any risk factors, BRONJ is known to occur spon-
taneously. The lingual side of the alveolus in mandible is a
predisposed site for spontaneous BRONJ, which is thought to be
triggered by an injury on the mucosa. Likewise, bony prominence
seen in palatal torus and mandibular torus is also susceptible to
BRONJ.
2.3. Glucocorticoids
The use of GCs with BP is known to raise the risk for
BRONJ because GCs suppress the activities of inﬂammatory cells
and immune cells to make the patients immunocompromized.
Since  GCs not only activate the osteoclasts, but also inhibit the
osteoblasts, the long-term use of GCs induce osteoporosis. That is
why patients undergoing GC therapy are also administered BP to
prevent osteoporosis. Rheumatoid arthritis (RA) is a typical disease
treated both with BP and GCs. Some of the patients with RA are also
treated with methotrexate (MTX) together with BP and GC. MTX is a
folic acid antagonist and used as an anti-cancer drug as well as anti-
rheumatic drug by inhibiting the inﬂammatory cells and decreasing
various cytokine productions, which is likely to increase the risk of
BRONJ. RA patients should be paid special attention for preventing
BRONJ.
3. Diagnostic criteria and stage classiﬁcation of BRONJ
3.1.  Criteria and stage
In  2007, criteria to diagnose BRONJ were provided in a position
paper by the American Association of Oral and Maxillofacial Sur-
geons as follows: (1) current or previous treatment with a BP; (2)
exposed bone in the maxillofacial region that has persisted for more
than 8 weeks; and (3) no history of radiation therapy to the jaws [5].
Although an exposure of necrotic bone, sequester, in the jaw is the
most prominent characteristic of BRONJ, it is occasionally observed
in chronic suppurative osteomyelitis of the jaw. That seems to be a
reason why  the criteria include the second point. The criterion (3)
is to exclude the possibility of osteoradionecrosis of the jaw.
The  position paper in 2007 also proposed a staging classiﬁca-
tion of BRONJ, stage 1, stage 2, and stage 3. Stage 1 shows only an
exposure of the bone without infectious signs. Stage 2 includes not
T. Ikebe / Oral Science Interna
Table 1
Comparison of the level between jaw inﬂammation and bisphosphonate-related
osteonecrosis of the jaw (BRONJ).
Category Level of the lesion
Alveolus Jaw body
Ostitis Alveolar ostitis Periostitis
Periodontitis
Abscess Gingival  abscess Subperiosteal abscess
Alveolar abscess
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it is important to ﬁnd out the cases of stage 0 as early as possible
and prevent them from progressing to the later stages. Hutchinson
F
iBRONJ Stage 2 Stage 3
nly a bone exposure, but also inﬂammatory symptoms by bacte-
ial infection such as pain and swelling. The extent of the lesion
n stage 2 is limited in the alveolar bone. When the lesion extends
o the jaw itself beyond the alveolar level, then, it will be classi-
ed to stage 3, where the bone necrosis or osteolysis may  extend
o the inferior border of mandible with or without extraoral ﬁs-
ula and pathological fracture. The difference between stage 2 and
tage 3 will be similar to that between periodontitis and periostitis,
epending on the affected area (Table 1).
.2. Stage 0
All  the stages of BRONJ require an exposed bone as a deﬁnition.
owever, it is known that there have been patients taking oral BP
ho have no bone exposure in the jaw, but suffered from some non-
peciﬁc and refractory symptoms such as diffuse alveolar swelling,
ingival redness, or internal dental ﬁstula whose origins are not
dentiﬁed. These symptoms have occasionally subsided after the
iscontinuation of BP therapy. The American Association of Oral
nd Maxillofacial Surgeons position paper in 2009 added a stage
 into the BRONJ staging for the cases with no clinical evidence
f necrotic bone, but nonspeciﬁc clinical ﬁndings and symptoms
12]. Fig. 1 shows a plausible explanation about the development
f stage 0. In stage 0, an open alveolar socket may  persist after tooth
xtraction, where the surface of the socket is concealed with gran-
lation tissues, but the most part of the bare socket is left behind
ith a bony surface, presumably because the thickened lamina dura
13], which cannot be resorbed by BP, may  prevent the inﬂamma-
ory cells from inﬁltrating, impair the wound healing processes, and
llow the infection to persist (Fig. 1).
ig. 1. What happens in the jaw of Stage 0? Thickened lamina dura will prevent white bloo
n  delayed wound healing and persistent infection.tional 10 (2013) 1– 8 3
4.  Relationship between stage 0 and suppurative
osteomyelitis of the jaw
Dentists  or oral and maxillofacial surgeons may  diagnose
the patients with stage 0 simply as suppurative periostitis or
osteomyelitis of the jaw, being unaware of their BP administration.
If stage 0 lesion is a precursor of BRONJ, bacterial infection may play
a critical role in the initiation of BRONJ.
Kos et al. [14] reported that when patients with osteomyelitis
of the jaws were divided into two  groups, the ones undergo-
ing BP treatment and the others taking no BP, Actinomyces was
signiﬁcantly detected on the exposed necrotic bones in the BP-
administered patients, suggesting the involvement of Actinomyces
in BRONJ. Ganguli et al. [15] suggest the afﬁnity of bacteria to
BP by showing increased adhesion of Staphylococcus aureus to
hydroxyapatite in joint prostheses coated with pamidronate. On
the other hand, Hansen et al. [16] also detected Actinomyces in the
necrotic bones of BRONJ as well as osteoradionecrosis in an equally
high frequency. Both necrotic bones from BRONJ and suppurative
osteomyelitis of the jaws were found to be covered with the bac-
terial bioﬁlms, but, Actinomyces predominated in the bioﬁlm from
suppurative osteomyelitis while the bioﬁlm from BRONJ included
more diverse bacterial organisms in addition to fungal organisms
not observed in suppurative osteomyelitis [17]. Although it remains
unknown whether bacterial infections including Actinomyces occur
primarily or secondarily in the BRONJ process, infection is likely to
worsen the symptoms of BRONJ. Thus, BRONJ stage 0 should be
initially treated with antibacterial mouth rinse and antibiotics.
As  mentioned below, BP inhibits the growth of vascular
endothelial cells and impairs the angiogenesis in bone and perios-
teum. The decrease in blood supply may  lead to avascular necrosis
of the jaw in BRONJ, which is like osteoradionecrosis of the jaws.
But, it is unlikely that avascular and aseptic necrosis of the bones is a
primary cause of BRONJ since some infectious lesions such as gingi-
val abscess often precede the development of BRONJ in many cases
[18], and stage 0 of BRONJ usually shows some infection signs. Saia
et al. [19] reported that among 60 cases of tooth extraction under
BP treatment, BRONJ occurred in 3 cases within 3 months, suggest-
ing that suppurative osteomyelitis might be the most inﬂuential
risk factor to bring out BRONJ.
Regardless  of whether bacterial infection causes BRONJ or not,et al. found the radiographic features with panoramic radiography
and computed tomography (CT), including diffuse osteosclerosis,
d cells from inﬁltrating and granulation tissue from forming in the socket, resulting
4 T.  Ikebe / Oral Science Interna
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mig. 2. Bisphosphonate (BP) targeting the mevalonate pathway. FPP, farnesyl
iphosphate;  PP, pyrophosphate.
hickened lamina dura, prominence of the inferior alveolar canal,
nd cortical disruption, in 10 cases among 30 patients with stage 0
20]. In my  opinion, hence, CT or cone beam CT seems to be useful
o detect these initial changes in the bones for the early diagnosis
f stage 0.
.  Mechanism of nitrogen-containing BP actions
The molecular target of nBP is a farnesyl diphosphate synthase
FPP synthase) in osteoclasts [2,21,22]. At ﬁrst, nBP was supposed
o inhibit the mineral dissolution by its binding to mineral com-
onents outside osteoclasts, but now it is known that nBP enters
nto the osteoclasts to inhibit the activity of FPP synthase which is
n enzyme involved in mevalonate pathway of osteoclasts (Fig. 2).
his effect of nBP was found in the research for an agent to lower
he level of serum cholesterol which is synthesized through meval-
nate pathway [2]. FPP synthase is an enzyme to convert geranyl
iphosphate to farnesyl diphosphate, which is in turn converted to
eranylgeranyl diphosphate. Geranylgeranyl diphosphate activates
he small GTPases, such as Rab, Rac, Ras, and Rho, through their iso-
renylation and geranylgeranylation. Small GTPases then regulate
he cytoskeletal arrangement, vesicular trafﬁcking, and membrane
ufﬂing which are involved in the processes of bone resorption by
steoclasts, including their migration to bones, adhesion on bone
urface and transportation of bone-resorbing enzymes to the ruf-
ed border. Therefore, the inhibition of FPP synthase with nBP can
revent osteoclasts from destructing the bones (Fig. 2).
There  may  be evidence to show that nBP disturbs the cytoskele-
al regulation. Weinstein et al. observed the osteoclasts in the
one-biopsy specimens of iliac bone obtained from healthy post-
enopausal women receiving 3-year oral alendronate therapy,
ompared with the placebo-controlled ones in a doubled-blind,
andomized trial [23]. In theory, it was expected that there would
e few osteoclasts in the bones from the patients taking nBP. Sur-
risingly, however, the number of the abnormal osteoclasts, which
ere giant, hypernucleated (with 20–40 nuclei), detached from
one surface, increased as the cumulative dose of alendronate
ncreased. Of these giant osteoclasts, 20–37% were apoptotic. They
uggest that nBP protracts the apoptosis of osteoclasts, where cell
usion continues to generate the distinctive morphology such as
iantism and hypernucleation. These features may  be attributed to
BP-mediated loss of small GTPase.
Such an increase in the number of giant, hypernucleated osteo-
lasts is also observed in the bones from patients with Schönberg
isease or autosomal dominant osteopetrosis type II, in which the
bility of osteoclasts to decay bone is impaired because of the muta-
ions in CLCN7 gene encoding a chloride channel [24]. nBP may
nhibit the function of CLCN7 [25]. Hansen et al. [16] also found
any osteoclasts in the necrotic bones from the BRONJ patientstional 10 (2013) 1– 8
administered with pamidronate or zoledronate. These data sug-
gest that nBP brings about the functional disorder, rather than the
depletion, of osteoclasts.
6.  Other target cells of BP
Although osteoclasts have been thought to be a speciﬁc target
of nBP, it is difﬁcult to attribute the occurrence of exposed bone
necrosis only to osteoclast disorder. Some other cells are thought
to take part in establishing BRONJ.
6.1. Osteoblasts
Osteoclasts are known to indirectly assist bone formation,
where osteoclastic bone resorption can release some growth factors
buried in the bone, which stimulate osteoblasts to make bones [26].
The cooperation of osteoclasts with osteoblasts, which is called
“coupling”, is thought to be essential for bone turnover. Thus, the
loss of osteoclasts is likely to impair the activity of osteoblasts,
resulting in the bone turnover arrest to osteonecrosis. On the
other hand, the direct effects of nBP on osteoblasts have also been
investigated. Zoledronate inhibited the growth and viability of cul-
tured osteoblasts [27,28], while pamidronate and zoledronate were
reported to inhibit the cell growth, but increase the bone formation
of immortalized fetal osteoblasts [29]. The damage to osteoblasts
may be associated with the occurrence of BRONJ, which hypoth-
esis may  be supported by the report that parathyroid hormone
might improve the BRONJ by stimulating osteoblasts, as mentioned
below.
6.2. Osteocytes
Allen and Burr [30] examined the bone matrix in the mandible
from beagle dogs treated with clinically relevant doses of daily
oral alendronate for 3 years and found signiﬁcant amounts of
necrotic bone matrix in approximately 25% of nBP-treated ani-
mals, which were predominantly present in the alveolar portion of
the mandible. The non-viable bone matrix showed empty lacunae
without osteocytes. It has been reported that ﬂuorescently labeled
risedronate injected intravenously into mice was observed around
the lacunae [31]. Because osteocytes are the most abundant bone
cells and form an intricate communication network throughout the
bone matrix, where osteocytes are thought to provide a signal to
osteoclasts to clean up the necrotic bones, the loss of osteocytes
may play a role in the pathophysiology of BRONJ [32]. It is likely that
the micronecrosis of the bone may  accumulate in large amounts
because of the lack of osteocyte–osteoclast communication [33,34].
6.3. Vascular endothelial cells
It is assumed that BP inhibits bone angiogenesis by suppress-
ing the growth of vascular endothelial cells to result in avascular
necrosis of the bone. There are a number of reports to show that nBP
directly inhibits angiogenesis in vitro or in vivo [35,36,28] although
the studies on the effects of nBP on angiogenesis in bone mar-
row and periosteum of the jaw remain to be done [37]. nBP may
also exert indirect effects on the suppression of bone angiogene-
sis since osteoclasts may  be required to make vessels pass through
bone matrix [38]. This importance of nBP-mediated inhibition of
angiogenesis in the jaw could be supported by the reports that the
administration of zoledronate reduced the serum levels of vascular
endothelial growth factor (VEGF) in patients with bone metasta-
sis [39] and that bevacizumab, an anti-VEGF antibody, may induce
osteonecrosis of the jaw [40].
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.4. Keratinocytes
nBP is reported to inhibit the growth of cultured keratinocytes
41]. nBP decreased the number of p63-positive keratinocyte pro-
enitor cells and prevented the gingival ﬁbroblasts from producing
eratinocyte growth factor (KGF) [42,43]. It is presumed that
nﬂammation in the jaws, i.e. tooth extraction, releases the nBP
uried in the bones, which in turn inhibits the keratinocyte growth
o worsen the exposure of bones, especially in patients with an
lcer or an injury formed on the mucosa by unsuitable dentures.
he mucosal damage with nBP is demonstrated in a case that the
ontact of nBP on mucosa induced stomatitis in patients who had
he habit to hold the alendronate tablets in the mouth for a while
efore swallowing them [44,45].
.5. Macrophages/monocytes
Since osteoclasts differentiate from macrophage/monocyte lin-
age, it is plausible that nBP inhibits the activity of macrophages.
ctually, nBP inhibited the production of cytokines in macrophages
nd monocytes [31]. The differentiation of dendritic cells, a
acrophage lineage, was interfered with by nBP [46,47]. These
acrophages/monocytes play an important role in the self-defense
ystem of immunity as antigen-presenting cells. Thus, nBP may
uppress the immunological reactions to make bones susceptible
o bacterial infection. In this respect, the reason why GC is a risk fac-
or for BRONJ is thought to be attributed to its immunosuppressive
ction  [48,49]. In addition, it is likely that nBP inhibits the differ-
ntiation from macrophage/monocyte to osteoclast. Kimachi et al.
50] reported that zoledronate inhibited the tumor necrosis factor-
-induced differentiation of a murine macrophage/monocyte cell
ine, Raw264.7 to mature osteoclasts.
. Why  does BRONJ occur in the jaws?
It is thought that jaw is the most predisposed to BP-related
steonecrosis because (1) the turnover rate of jaws, especially alve-
lar bones, is so rapid and (2) jaws have teeth and gum that may
ecome an easy entrance for bacterial infection [51].
.1.  Bone turnover rate
The  remodeling rates of the cortical bone in the jaw are 10–20
imes higher than in the cortex of iliac crest in humans [52,53]. The
evel of intracortical bone remodeling in the mandible was  found
o be more than 10 times higher than in the tibial cortex in dogs,
specially, the alveolar portion of the mandible having more than
 times higher rate of turnover than in the other portions of the
andible [37]. In contrast, some articles show that the turnover
f the jaw is not the highest among the bones. Huja and Beck [54]
eported that the bone formation rate of the femur is higher than
hat of the mandible and maxilla in dogs. In athymic rats, the uptake
f ﬂuorescently labeled pamidronate to the bones and the release
f it per unit calcium were lower in the oral bones than in the axial
ones [55]. Apart from the controversy, bone damage such as sur-
ical intervention and infection may  accelerate the turnover rate of
he jaw.
When ﬂuorescent pamidronate was injected intravenously into
ice, 90% of the ﬂuorescent signal localized to bone within 2–6 h of
njection, where more signals were detected and retained longer in
he mandible rather than in the femur [56]. Moreover, ﬂuorescent
amidronate was found to be deposited in the alveolar bone and
one surrounding the periodontal ligament and molar roots [56].
aken together, alveolar bone of the mandible is most susceptibletional 10 (2013) 1– 8 5
to  the nBP effects because of rapid turnover rate and high afﬁnity
to nBP.
7.2. Vulnerability of the jaw to bacterial infection
Among all the bones, jaw seems to be the most liable to bacte-
rial infection since mucosa covering the alveolar bone is very thin
and vulnerable, and teeth easily become a pathway for bacteria
from the outside into the bone. Although it is certain that bacterial
infection makes BRONJ worse, it remains to be determined whether
bacterial infection precedes osteonecrosis of the jaw. Aghaloo et al.
[57] found that the necrosis of the alveolar bones developed in the
rats, which underwent the placement of a wire ligature around
the crown of maxillary molar in a periodontal disease model, after
intraperitoneal injection with zoledronate. The necrotic bones were
not exposed in these rats whereas the control animals showed the
resorption of alveolar bone, but not any osteonecrosis. The results
imply that periodontitis, which is presumably infection-related,
can trigger the osteonecrosis.
When  periodontitis occurs, inﬂammatory cells are recruited to
the sites to eliminate the causative pathogens. However, the block-
ade of bone resorption with BP may  make it difﬁcult for these
cells to access to the pathogens, allowing the infection to persist.
The resulting accumulation of bacterial toxins and inﬂammation-
generated superoxides will promote the bone necrosis. Thus,
bacterial infection is likely to be involved in the formation of BRONJ.
From these assumptions, it seems to be reasonable to treat
BRONJ with thorough local rinse and antibiotic administration as a
ﬁrst step to control the infection.
8. Confused effect of nBP on osteomyelitis of the jaw
On  the other hand, pamidronate is used to treat patients with
chronic non-bacterial osteomyelitis (CNO), including chronic recur-
rent multifocal osteomyelitis (CRMO), SAPHO (synovitis, acne,
pustulosis, hyperostosis, and osteitis), and juvenile diffuse scle-
rosing osteomyelitis (DSO), which occasionally occur in the jaws
[58–61]. Although the causative mechanism of CNO remains
unknown, the effectiveness of BP on CNO may rather support the
hypothesis that bacterial infection is involved in the initiation of
BRONJ. BP can cure non-bacterial osteomyelitis while BP worsens
suppurative osteomyelitis to BRONJ.
When dental surgical procedures were applied to 22 patients
with osteogenesis imperfecta who  underwent BP therapy, no
BRONJ cases were observed [62]. It remains unknown why  the inci-
dence of BRONJ is so low when BP therapy is applied to osteogenesis
imperfecta and CNO.
9.  Pathophysiological mechanism of BRONJ
Based on our knowledge as summarized above, the putative
mechanism of BRONJ formation is summarized in Fig. 3. After
administration, nBPs deposit and accumulate in the alveolar bone,
which have a higher turnover rate. During a physiological remod-
eling of the bone, osteocytes are exposed to the buried nBPs
and damaged, leading to the micronecrosis of the bones. The
amounts of the necrotic bones gradually increase because osteo-
clasts cannot degrade the necrotic bones. When tooth extraction
is performed, then, the inﬂammatory cytokines are produced
in the periodontal tissues, which exert the serial inﬂammatory
reactions, where the tissue-degrading proteases may be involved
in the increased release of nBPs from the alveolar bones. The
released nBPs may  block angiogenesis and delay the migration of
neutrophils, macrophages, and osteoclast progenitors to the site,
inhibiting the formation of granulation tissues, which are needed
6 T.  Ikebe / Oral Science International 10 (2013) 1– 8
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or wound healing and bone remodeling. The poor vascularity and
equestration in periodontal tissues makes the bacterial infection
ersist because the recruitment of neutrophils and lymphocytes
re blocked. The ﬁstula formation to discharge pus inside bone is
lso prevented because of the lack of osteoclasts. The persisting
nfection promotes the increase in osteonecrosis while the uncou-
ling between osteoblasts and osteoclasts causes the suppression
f bone turnover. The released nBPs ﬁnally inhibit the proliferation
f mucosal keratinocytes, leading to the exposure of necrotic bones.
0. Treatment of BRONJ
The  strategies for the treatment of BRONJ have been proposed in
he position papers depending on the stages [5,9,12]. BRONJ stage
 may  be treated with a surgical removal of the jaw which contains
he necrotic bones while a conservative therapy is indicated for
tage 1 or stage 2. One of the basic conservative therapies is a local
rrigation with saline or the use of oral antimicrobial rinse.
0.1.  Drug holiday
In  the patients treated with oral BP therapy, a drug holiday, dis-
ontinuation of BP therapy, seems to be effective to restore bone
urnover of the jaw and support the treatment of BRONJ. In the
osition papers, the discontinuation of BP is recommended for
ore than 3 months before tooth extraction if the patients have
eceived oral BP therapy for more than 3 years. It is expected that
one turnover of the jaw once disturbed with BP will be recovered
uring a 3-month drug holiday. This concept is supported by the
eport of Marx et al. [63], where the serum concentrations of CTX,
hich is a cross-linking peptide of type I collagen, released from
he bones during bone resorption and utilized as a marker of bone
urnover, were measured in the patients with BRONJ. They found
hat the serum concentrations of CTX increased from 72.4 pg/ml
o 150 pg/ml, which is in the level for low risk of BRONJ, with the
iscontinuation of BP for 3–4 months. Hence, a 3-month holiday
rom BP may  restore bone turnover of the jaw. In fact, Treister
nd Woo  [64] reported that the mucosa completely covered the
xposed bone in stage 2 of BRONJ 4 months after the discontinu-
tion of BP and local rinse. Discontinuation of oral BP therapy is
hought to be the ﬁrst step to care for patients with BRONJ.(BP)-related osteonecrosis of the jaw development.
It remains controversial whether serum CTX concentration can
be used as a predictive marker for BRONJ, because the values of CTX
concentration seem to vary from case to case [65,66].
10.2. Hyperbaric oxygen
Since  hyperbaric oxygen (HBO) is known to be effective adjunc-
tive therapy for the treatment of chronic osteomyelitis and
osteoradionecrosis of the jaw, then, it has also been applied to the
treatment of BRONJ. The efﬁcacy of HBO in the treatment of BRONJ
has not yet been elucidated, but may  be promising because it is
expected to improve the hypoxia condition in the jaw and gener-
ate reactive oxygen species (ROS) to stimulate the differentiation
and activity of osteoclasts [67].
10.3. Teriparatide (recombinant human parathyroid hormone
1–34)
Recently, it has been reported that BRONJ was dramatically
improved with teriparatide therapy [68–70]. Teriparatide consists
of 1–34 amino acids of recombinant human parathyroid hormone
(PTH) (a full PTH includes 84 amino acids), and has been used for
the treatment of GC-induced osteoporosis. PTH plays an essential
role in the regulation of calcium metabolism. When PTH levels are
continuously elevated, bones are severely degraded to increase the
serum calcium concentration because of osteoclast activation. In
contrast, intermittent pulsatile administration of PTH stimulates
the differentiation and function of osteoblasts, rather than osteo-
clasts, to lead to anabolic effects on bone [71]. Hence, intermittent
subcutaneous injection of teriparatide once a day is expected to
promote bone formation. In the treatment of BRONJ, teriparatide
may cause activation of osteoblasts to restore the bone turnover
once inhibited with nBP, and promote the production of receptor
activation of nuclear factor-kB ligand (RANKL) from osteoblasts to
reactivate osteoclasts.
10.4.  Prospective therapyAs  mentioned above, nBPs impair osteoclasts through inhibiting
FPP synthase in the mevalonate pathway (Fig. 2). If a downstream
molecule of farnesyl diphosphate whose generation is mediated
T. Ikebe / Oral Science International 10 (2013) 1– 8 7
Fig. 4. A role of osteoclasts in self-defense of the jaw. Osteoclasts play an impor
Table  2
List  of the drugs related to osteonecrosis of the jaw.
Drugs related to osteonecrosis of the jaw
Bisphosphonate
Glucocorticoid
Bevacizumab
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ith FPP synthase in the mevalonate pathway is supplied into the
BP-treated osteoclasts, the inhibitory effects of nBP on osteoclasts
ould be compensated. Kimachi et al. [50] found that the addition
f geranylgeranyl diphosphate, which is a downstream metabo-
ite of FPP synthase, dramatically restored the motility and RANK
xpression of the cultured osteoclast precursors which were once
nhibited with zoledronate, implying that geranylgeranyl diphos-
hate neutralizes the effect of nBP. Such an intermediate metabolite
n the mevalonate pathway is expected to become a drug to revive
he osteoclasts in the patients with BRONJ [72].
1. Drug-related osteoclastic disease of the jaw
Recently, it has been suspected that ONJ is induced not only by
BP, but also by the molecule-targeting drugs, which are newly
eveloped, such as denosumab, anti-RANKL antibody, and beva-
izumab, an anti-VEGF antibody [2,40,73]. The number of case
eports about ONJ occurring in cancer patients treated with these
ew anti-cancer drugs appears to be increasing (Table 2). The
ncidence of ONJ was 0.3–0.4% in the patients with breast can-
er undergoing bevacizumab therapy whereas the administration
f bevacizumab together with nBP increased the ONJ incidence
o 0.9–2.4% [74]. The combination of nBP with sunitinib, which
nhibits tyrosine kinase involved in various growth factor receptors
o treat renal cell carcinoma, is reported to raise the risk of BRONJ,
here sunitinib-induced oral mucositis is thought to trigger the
ccurrence of BRONJ [75].
According  to recent advances in medical science, a number of
ew drugs have been developed and applied to patients, espe-
ially those with cancer. Our society will speed up this situation
n the future. On the other hand, the more new drugs are devel-
ped, the more adverse effects will emerge. New drugs may  induce
ew diseases such as BRONJ. It is plausible that the jaw is the most
ulnerable site to the adverse effects of new drugs because of its
pecial anatomical characteristics. Furthermore, a jaw is composed
f a variety of cells, all of which should take part in the life of the jaw.
ven damage only to osteoclasts with BP will disturb the network
f each cell through the jaw. From this viewpoint, our experiences
[
[tant role in excluding bacteria from the inside of jaw. BP, bisphosphonate.
about  BRONJ give birth to a concept that osteoclasts play a criti-
cal role in the self-defense of the jaw (Fig. 4). Hence, it suggests
that BRONJ or other related jaw disease is newly classiﬁed as drug-
related osteoclastic disease of the jaw. We  should prepare for the
challenges from such new diseases.
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